China Resources Pharmaceutical Group Management
Management criteria checks 3/4
China Resources Pharmaceutical Group's CEO is Xiaosong Bai, appointed in Jan 2022, has a tenure of 2.25 years. total yearly compensation is CN¥2.55M, comprised of 98% salary and 2% bonuses, including company stock and options. directly owns 0.003% of the company’s shares, worth HK$956.96K. The average tenure of the management team and the board of directors is 2.4 years and 3.8 years respectively.
Key information
Xiaosong Bai
Chief executive officer
CN¥2.6m
Total compensation
| CEO salary percentage | 98.0% |
| CEO tenure | 2.3yrs |
| CEO ownership | 0.003% |
| Management average tenure | 2.4yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To CN¥0.1697
Apr 14
China Resources Pharmaceutical Group's (HKG:3320) Dividend Will Be Increased To CN¥0.1697
Mar 28China Resources Pharmaceutical Group Limited's (HKG:3320) Shares May Have Run Too Fast Too Soon
Jan 28We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Dec 06Does China Resources Pharmaceutical Group (HKG:3320) Have A Healthy Balance Sheet?
Sep 07Does This Valuation Of China Resources Pharmaceutical Group Limited (HKG:3320) Imply Investors Are Overpaying?
Aug 02With EPS Growth And More, China Resources Pharmaceutical Group (HKG:3320) Makes An Interesting Case
May 26These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
May 05China Resources Pharmaceutical Group's (HKG:3320) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 04Is There An Opportunity With China Resources Pharmaceutical Group Limited's (HKG:3320) 24% Undervaluation?
Jan 24Is China Resources Pharmaceutical Group (HKG:3320) Using Too Much Debt?
Dec 15China Resources Pharmaceutical Group Limited's (HKG:3320) Intrinsic Value Is Potentially 97% Above Its Share Price
Oct 18China Resources Pharmaceutical Group (HKG:3320) Takes On Some Risk With Its Use Of Debt
Aug 27China Resources Pharmaceutical Group (HKG:3320) Has Announced That It Will Be Increasing Its Dividend To HK$0.15
May 29China Resources Pharmaceutical Group (HKG:3320) Is Increasing Its Dividend To HK$0.15
May 02China Resources Pharmaceutical Group's (HKG:3320) Upcoming Dividend Will Be Larger Than Last Year's
Apr 07China Resources Pharmaceutical Group (HKG:3320) Has A Somewhat Strained Balance Sheet
Mar 31Are Investors Undervaluing China Resources Pharmaceutical Group Limited (HKG:3320) By 23%?
Feb 21Here's Why China Resources Pharmaceutical Group (HKG:3320) Can Manage Its Debt Responsibly
Dec 07China Resources Pharmaceutical Group Limited (HKG:3320) Shares Could Be 32% Below Their Intrinsic Value Estimate
Nov 10These 4 Measures Indicate That China Resources Pharmaceutical Group (HKG:3320) Is Using Debt Reasonably Well
Aug 29Is China Resources Pharmaceutical Group Limited (HKG:3320) Trading At A 21% Discount?
Aug 03Is China Resources Pharmaceutical Group Limited (HKG:3320) A Good Fit For Your Dividend Portfolio?
May 03Is China Resources Pharmaceutical Group (HKG:3320) A Risky Investment?
Apr 12Is China Resources Pharmaceutical Group Limited's (HKG:3320) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Mar 17An Intrinsic Calculation For China Resources Pharmaceutical Group Limited (HKG:3320) Suggests It's 24% Undervalued
Feb 14If You Had Bought China Resources Pharmaceutical Group's (HKG:3320) Shares Three Years Ago You Would Be Down 63%
Jan 17
We Think China Resources Pharmaceutical Group (HKG:3320) Is Taking Some Risk With Its Debt
Nov 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | CN¥4b |
| Jun 30 2023 | n/a | n/a | CN¥4b |
| Mar 31 2023 | n/a | n/a | CN¥4b |
| Dec 31 2022 | CN¥3m | CN¥2m | CN¥4b |
Compensation vs Market: Xiaosong's total compensation ($USD352.33K) is below average for companies of similar size in the Hong Kong market ($USD533.40K).
Compensation vs Earnings: Insufficient data to compare Xiaosong's compensation with company performance.
CEO
Xiaosong Bai (52 yo)
2.3yrs
Tenure
CN¥2,550,953
Compensation
Mr. Xiaosong Bai serves as Non-Independent Director of China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. since March 3, 2022. He serves as Executive Director and Chief Executive Officer at China Re...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 2.3yrs | CN¥2.55m | 0.0032% CN¥ 957.0k | |
| VP & Executive Director | 2.6yrs | CN¥2.76m | no data | |
| CFO & Executive Director | less than a year | no data | no data | |
| Chief Information Officer & VP | 10.3yrs | no data | no data | |
| Chief Legal Advisor | 10.1yrs | no data | no data | |
| Company Secretary | less than a year | no data | no data | |
| Vice President | no data | no data | no data | |
| Vice President of CR Pharma & Chairman of China Resources Boya | no data | no data | no data |
2.4yrs
Average Tenure
51yo
Average Age
Experienced Management: 3320's management team is considered experienced (2.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 2.3yrs | CN¥2.55m | 0.0032% CN¥ 957.0k | |
| VP & Executive Director | 2.6yrs | CN¥2.76m | no data | |
| CFO & Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | 7.8yrs | CN¥265.08k | no data | |
| Non-Executive Director | 2.3yrs | no data | no data | |
| Independent Non-Executive Director | 7.8yrs | CN¥265.08k | no data | |
| Independent Non-Executive Director | 7.8yrs | CN¥265.08k | no data | |
| Chairman of China Resources Double-Crane Pharmaceutical Co. | 5.3yrs | no data | no data | |
| Non-Executive Director | 1.2yrs | no data | no data | |
| Independent Non-Executive Director | 6.7yrs | CN¥265.08k | no data | |
| Chairman | 4.5yrs | CN¥2.62m | 0.0048% CN¥ 1.4m | |
| Non-Executive Director | 3.1yrs | no data | no data |
3.8yrs
Average Tenure
57.5yo
Average Age
Experienced Board: 3320's board of directors are considered experienced (3.8 years average tenure).